20 mg

DRUG7 trials

Sponsors

National Institute Of Cardiology, Pfizer Inc., Centrum Medyczne Ksztalcenia Podyplomowego, Instytut Hematologii I Transfuzjologii, Medical University Of Gdansk

Conditions

Acute ischemic strokeBioequivalence Study&#44Compulsive Sexual Behaviour DisorderDiffuse large B-cell lymphoma) and aggressive B-cell lymphomas (HGBCLDiffuse large B-cell lymphomas (DLBCLEROSIVE ESOPHAGITISFontan circulation is createdHeart 2018). The reduced exercise capacity of patients and the development of Fontan circulatory complications affect both the quality of life and the prognosis of adult patients with univentricular heart.

Phase 1

Single-Dose, Fed Bioequivalence Study of MYLAN Rivaroxaban Tablets 20 mg (20 mg; Mylan) and XareltoÂ® 20 mg (20 mg; Bayer) in Healthy Adult Volunteers

Active, not recruitingTCTR20201224002

International Bio Service Co.,Ltd.Bioequivalence Study&#44

Start: 2021-04-05Target: 36Updated: 2026-03-30

Phase 2

AN EXPLORATORY, MULTICENTER, RANDOMIZED,DOUBLE BLIND STUDY OF CLINICAL OUTCOMES,TOLERABILITY, AND SAFETY OF 2 DOSES OF ORAL PANTOPRAZOLE IN PEDIATRIC PARTICIPANTS AGED 1 TO 11 YEARS AND 12 TO 17 YEARS WHO REQUIRE MAINTENANCE THERAPY FOR HEALED EROSIVE ESOPHAGITIS

CompletedCTIS2023-508770-28-00

Pfizer Inc.EROSIVE ESOPHAGITIS

Start: 2021-10-05End: 2025-11-05Target: 18Updated: 2025-05-09

A phase II efficacy and safety study of cell-free circulating tumor DNA-guided commencement of second-line treatment in patients with DLBCL/HGBCL relapse

Not yet recruitingCTIS2024-518275-64-00

Instytut Hematologii I TransfuzjologiiDiffuse large B-cell lymphoma) and aggressive B-cell lymphomas (HGBCL, Diffuse large B-cell lymphomas (DLBCL, High-grade B-cell lymphoma) originate from mature B-cells at various stages of terminal differentiation

Target: 340Updated: 2025-11-24

A multicentre, parallel group, randomised, double blind, placebo-controlled, phase II study evaluating the efficacy and safety of reperfusion thrombolytic therapy with intravenous recombinant tissue plasminogen activator (rtPA) for ischaemic stroke in patients on the non-vitamin K antagonist oral anticoagulant after reversing anticoagulant activity with the specific antidote

RecruitingCTIS2024-518509-17-00

Medical University Of GdanskAcute ischemic stroke

Start: 2022-01-10Target: 300Updated: 2024-12-09

Phase II, Multicenter Study to Assess Safety and Efficacy of Combination of Sargramostim with D-VCd Therapy (Daratumumab, Cyclophosphamide, Bortezomib, Dexamethasone) in Untreated Patients with Light Chain Amyloidosis

Active, not recruitingCTIS2024-518658-18-00

Medical University Of Warsawa 3-week treatment with sargramostim resulted in improved cognitive function, a relationship between high levels of GM-CSF in the synovial fluid and a lower risk of developing Alzheimer's disease, based on the results of the ANDROMEDA phase III clinical trial +22

Start: 2023-07-26Target: 20Updated: 2025-09-11

Phase 3

The use of sildenafil in patients with univentricular heart after Fontan operation - a pilot SINFON-POL study.

RecruitingCTIS2023-503913-31-01

National Institute Of Cardiologyand above all from the progressive dysfunction of a single systemic ventricle and the lack of a subpulmonary chamber ensuring pulsatile pulmonary flow. Although the Fontan operation in many patients with an univentricular heart is a very good method of palliative treatment, and consequently to reduced cardiac output and worsened exercise tolerance. Thus, and in multi-centre studies. Among other things +16

Start: 2025-06-27Target: 60Updated: 2025-07-22

Pharmacological treatment of compulsive sexual behaviour disorder

WithdrawnCTIS2024-514490-22-00

Centrum Medyczne Ksztalcenia PodyplomowegoCompulsive Sexual Behaviour Disorder

Target: 410Updated: 2024-09-30